503 related articles for article (PubMed ID: 25686010)
1. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles.
Kim JH; Kim Y; Bae KH; Park TG; Lee JH; Park K
Mol Pharm; 2015 Apr; 12(4):1230-41. PubMed ID: 25686010
[TBL] [Abstract][Full Text] [Related]
2. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
Yu DH; Lu Q; Xie J; Fang C; Chen HZ
Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444
[TBL] [Abstract][Full Text] [Related]
3. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging.
Bae KH; Lee JY; Lee SH; Park TG; Nam YS
Adv Healthc Mater; 2013 Apr; 2(4):576-84. PubMed ID: 23184673
[TBL] [Abstract][Full Text] [Related]
4. Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug.
Jang MK; Jeong YI; Nah JW
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):530-6. PubMed ID: 20801624
[TBL] [Abstract][Full Text] [Related]
5. New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation.
Rosière R; Van Woensel M; Gelbcke M; Mathieu V; Hecq J; Mathivet T; Vermeersch M; Van Antwerpen P; Amighi K; Wauthoz N
Mol Pharm; 2018 Mar; 15(3):899-910. PubMed ID: 29341619
[TBL] [Abstract][Full Text] [Related]
6. Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.
Qian J; Xu N; Zhou X; Shi K; Du Q; Yin X; Zhao Z
Int J Nanomedicine; 2019; 14():7431-7446. PubMed ID: 31686815
[TBL] [Abstract][Full Text] [Related]
7. An optimized two-vial formulation lipid nanoemulsion of paclitaxel for targeted delivery to tumor.
Chen L; Chen B; Deng L; Gao B; Zhang Y; Wu C; Yu N; Zhou Q; Yao J; Chen J
Int J Pharm; 2017 Dec; 534(1-2):308-315. PubMed ID: 28986321
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
[TBL] [Abstract][Full Text] [Related]
9. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
10. Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles.
Zheng J; Wan Y; Elhissi A; Zhang Z; Sun X
Pharm Res; 2014 Aug; 31(8):2220-33. PubMed ID: 24595496
[TBL] [Abstract][Full Text] [Related]
11. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
Pandey V; Gajbhiye KR; Soni V
Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
[TBL] [Abstract][Full Text] [Related]
12. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
[TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect.
Wu J; Zhao J; Zhang B; Qian Y; Gao H; Yu Y; Wei Y; Yang Z; Jiang X; Pang Z
Int J Nanomedicine; 2014; 9():5261-71. PubMed ID: 25419130
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
[TBL] [Abstract][Full Text] [Related]
16. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
18. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
19. Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
Khatri H; Chokshi N; Rawal S; Patel BM; Badanthadka M; Patel MM
Int J Pharm; 2020 Jun; 583():119386. PubMed ID: 32376440
[TBL] [Abstract][Full Text] [Related]
20. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
